Moderna (NASDAQ:MRNA) Price Target Cut to $155.00

Moderna (NASDAQ:MRNA) had its price target reduced by research analysts at Barclays from $168.00 to $155.00 in a research note issued on Friday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target indicates a potential upside of 79.03% from the stock’s previous close.

Several other equities research analysts also recently weighed in on the stock. Oppenheimer boosted their target price on shares of Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 12th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Thursday. Evercore ISI restated an “in-line” rating and set a $120.00 price objective on shares of Moderna in a research note on Thursday, June 27th. Royal Bank of Canada lifted their target price on Moderna from $135.00 to $160.00 and gave the stock an “outperform” rating in a research report on Monday, June 3rd. Finally, Piper Sandler reissued an “overweight” rating and set a $157.00 price target (down from $214.00) on shares of Moderna in a research report on Friday. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $126.59.

Moderna Trading Down 8.1 %

Shares of MRNA opened at $86.58 on Friday. Moderna has a one year low of $62.55 and a one year high of $170.47. The stock has a 50-day moving average price of $129.81 and a 200 day moving average price of $115.11. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.91 and a current ratio of 4.09. The company has a market capitalization of $33.18 billion, a P/E ratio of -5.53 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The company had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same period in the prior year, the company posted ($3.62) EPS. Moderna’s quarterly revenue was down 29.9% on a year-over-year basis. Sell-side analysts forecast that Moderna will post -7.46 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $121.68, for a total value of $1,825,200.00. Following the completion of the transaction, the director now owns 2,011,931 shares in the company, valued at approximately $244,811,764.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO James M. Mock sold 648 shares of Moderna stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total transaction of $105,280.56. Following the transaction, the chief financial officer now directly owns 5,726 shares of the company’s stock, valued at $930,303.22. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $121.68, for a total transaction of $1,825,200.00. Following the completion of the sale, the director now directly owns 2,011,931 shares of the company’s stock, valued at $244,811,764.08. The disclosure for this sale can be found here. Insiders have sold 396,239 shares of company stock valued at $55,563,937 in the last quarter. Corporate insiders own 15.70% of the company’s stock.

Institutional Trading of Moderna

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ogorek Anthony Joseph NY ADV bought a new position in shares of Moderna in the fourth quarter valued at $27,000. Arlington Trust Co LLC grew its holdings in shares of Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after acquiring an additional 290 shares during the last quarter. Cedar Wealth Management LLC raised its position in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the period. Westside Investment Management Inc. purchased a new stake in shares of Moderna during the first quarter valued at $32,000. Finally, Family Firm Inc. acquired a new position in shares of Moderna in the 2nd quarter valued at $33,000. 75.33% of the stock is owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.